Saturday, October 12, 2024
HomeLatest Pharma-NewsNew data at the ASCO20 reflects Roche’s commitment to cancer care

New data at the ASCO20 reflects Roche’s commitment to cancer care

May 07, 2020: “Roche announced that new data from clinical trials of 19 approved and investigational medicines across 21 cancer types, will be presented at the ASCO20 Virtual Scientific Program organised by the American Society of Clinical Oncology (ASCO), which will be held 29-31 May 2020.

A total of 120 abstracts that include a Roche medicine will be presented at this year’s meeting.

“At ASCO, we will present new data from many investigational and approved medicines across our broad oncology portfolio,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development.

- Advertisement -

“These efforts exemplify our long-standing commitment to improving outcomes for people with cancer, even during these unprecedented times.

By integrating our medicines and diagnostics together with advanced insights and novel platforms, Roche is uniquely positioned to deliver the healthcare solutions of the future.”

Together with its partners, Roche is pioneering a comprehensive approach to cancer care, combining new diagnostics and treatments with innovative, integrated data and access solutions for approved medicines that will both personalise and transform the outcomes of people affected by this deadly disease.

Key presentations
First results of tiragolumab, Roche’s novel cancer immunotherapy designed to bind to TIGIT, will be shared.

These results, from the phase II CITYSCAPE study, examine tiragolumab in combination with Tecentriq® (atezolizumab) compared with Tecentriq alone as an initial treatment for people with PD-L1-positive locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC).

In addition, updated five-year overall survival rates with Alecensa® (alectinib) in people living with treatment-naive anaplastic lymphoma kinase (ALK)-positive metastatic/advanced NSCLC will be presented.

With five approved lung cancer medicines and an extensive pipeline across multiple subtypes, Roche’s ultimate aim is to provide an effective treatment option for each person diagnosed with the disease, tailored to the unique characteristics of their tumours.

Studies featured from partnerships with Flatiron Health and Foundation Medicine demonstrate how the use of next-generation sequencing (NGS) may help inform treatment decisions, optimise testing and enable personalised therapy, including an ongoing additional study designed to prospectively link longitudinal, real-world clinical data with genomic, imaging and outcomes data for patients with advanced lung cancers.

The study is monitoring circulating tumour DNA (ctDNA) using FoundationOne® Liquid, and tumour tissue samples will be genomically profiled using FoundationOne® CDx.

Based on this year’s virtual format, Roche will be launching a virtual newsroom for journalists to access further information on our contribution to the ASCO20 Virtual Scientific Program, as well as the latest innovations and developments in Roche’s approach to accelerating progress in cancer care.

The newsroom will be available on Friday 29 May, 08:00 CEST, and open to journalists from outside the United States.”

Overview of key presentations featuring Roche medicines at ASCO 2020

https://www.roche.com/media/releases/med-cor-2020-05-07.htm

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular